LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice
Journal of Controlled Release · 2024-11 · 375 · 513-523
DOI: 10.1016/j.jconrel.2024.09.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Jiayin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Mice, Inbred NOD, RNA, Messenger, Glutamate Decarboxylase. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Islet-antigen-specific tolerization is a key goal of experimental immunotherapies for type 1 diabetes. mRNA-based vaccines have demonstrated the feasibility of RNA delivery in inducing antigen tolerance in autoimmune diseases. In this study, mRNA vaccine, encoded tandem glutamic acid decarboxylase 65 (GAD65) epitopes and cholera toxin B subunit (CTB-GADIII), prepared by an in vitro transcription (IVT) system and encapsulated with lipid nanoparticles (LNP), was intramuscularly administered to non-obese diabetic (NOD) and cyclophosphamide (Cy)-NOD mice respectively. The results showed that the mRNA vaccines significantly reduced the incidence rate of type 1 diabetes, delayed the disease progression, improved glucose tolerance, and protected pancreatic morphology and function compared with the controls. Meanwhile, the vaccines also reduced the levels of autoantibodies to glutamic acid decarboxylase (GADA) and insulin (IAA) in the serum. Furthermore, the proportion of CD4+ T helper cell subsets was modulated in the spleen of mice treated with mRNA vaccines, in correspondence with the increased levels of IL-10 and TGF-β in serum, suggesting the possible mechanism of immune tolerance. This study provides experimental evidence for the application of mRNA vaccines encoding self-antigens in the prevention or treatment of type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, China. Electronic address: zhiguisu707@cpu.edu.cn.
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Electronic address: wujie@cpu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Hu, Y., Chen, Y., Zhou, Z., Shen, Y., Wang, Y., Liu, Z., Li, X., Su, Z., & Wu, J. (2024). LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice. Journal of Controlled Release, 375, 513-523. https://doi.org/10.1016/j.jconrel.2024.09.020
Vancouver
Chen J, Hu Y, Chen Y, Zhou Z, Shen Y, Wang Y, et al. LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice. Journal of Controlled Release. 2024;375:513-523. doi:10.1016/j.jconrel.2024.09.020
BibTeX
@article{Chen2024,
author = {Chen, Jiayin and Hu, Yiqi and Chen, Yan and Zhou, Ziqi and Shen, Yiming and Wang, Yan and Liu, Zichuan and Li, Xianglong and Su, Zhigui and Wu, Jie},
title = {LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice},
journal = {Journal of Controlled Release},
year = {2024},
volume = {375},
pages = {513--523},
doi = {10.1016/j.jconrel.2024.09.020}
}
EUVIMED